分類: ACN Newswire

SAN FRANCISCO, CA & MUMBAI, Dec 2, 2024 - (ACN Newswire via SeaPRwire.com) - CleverTap, the all-in-one engagement platform, has released its market research report on “The State of App and Web User Experience Optimization”. The report sheds light on how digital-first brands are leveraging experimentation and personalization on their apps and websites to drive customer engagement and business growth. It also highlights roadblocks faced by marketers and product managers while experimenting with the UI, workflows, and functionality across apps and websites.For a thorough understanding of the current landscape, this report draws insights from a diverse group of respondents – with data gathered through structured surveys and in-depth interviews – representing organizations with over two million customers across 50+ countries. This includes VPs, CMOs, and product managers ranging from startups to large enterprises across various industries. – Together, they offer valuable insights into how businesses optimize app and web experiences to drive customer engagement and business growth.While 95% of surveyed product managers and 88% of marketers believe that the right user experience is essential for driving customer engagement and retention — many report significant challenges to effectively experimenting with app and web user experiences. Despite recognizing its importance, they reported difficulties such as limited resources, data gaps, and technical constraints that hinder their ability to innovate and deliver impactful user experiences. Other notable findings from the report include -81.9% of product managers rarely experiment with their app and web experiences before making changes to them. The top challenges quoted include lack of resources (46%), inadequate data and analytics (31%), and technical issues (19%)54% of product managers are unable to support marketers in experimenting with onboarding flows, banner placement, homepage content and other similar app and web experiences.81% of marketers believe it would make a significant impact if they could independently experiment with multiple variations of web and app experiences within a no-code framework provided by their product management function.Commenting on the report, Jacob Joseph, Vice President - Data Science, CleverTap said, “With consumer expectations constantly rising, brands need to go beyond perfecting their channel strategies and also focus on enhancing the in-app and web experiences to drive results from their marketing efforts. Since all channels ultimately lead users to the app or website, an unsatisfactory experience there can render all your efforts ineffective and become a missed opportunity. Personalization and experimentation on apps and websites are critical to reducing churn and driving growth, yet resource constraints and data gaps hinder marketers and product managers. We are committed to helping businesses navigate these challenges with CleverTap’s Product Experiences, which offers effortless ways to personalize and experiment with app and web experiences driving stronger engagement and lasting brand loyalty."For more information and insights download the report here. About CleverTapCleverTap is the leading all-in-one customer engagement platform that helps brands unlock limitless customer lifetime value. CleverTap is trusted by over 2000 brands like Decathlon, Domino’s, Levis, Jio, Emirates NBD, Puma, Croma (A Tata Enterprise), Swiggy, SonyLIV, Axis Bank, AirAsia, TD Bank, Ooredoo, and Tesco to help build personalized experiences for all their customers. The platform is powered by TesseractDB™ – the world’s first purpose-built database for customer engagement, offering speed and cost efficiency at scale.Backed by top-tier investors such as Accel, Peak XV Partners, Tiger Global, CDPQ and 360 One, the company is headquartered in San Francisco, with presence across Seattle, London, São Paulo, Bogota, Mexico, Amsterdam, Sofia, Dubai, Mumbai, Bangalore, Singapore, Vietnam, and Jakarta.For more information, visit clevertap.com or follow us on:LinkedIn: https://www.linkedin.com/company/clevertap/  X: https://twitter.com/CleverTap  Forward-Looking StatementsSome of the statements in this press release may represent CleverTap's belief in connection with future events and may be forward-looking statements, or statements of future expectations based on currently available information. CleverTap cautions that such statements are naturally subject to risks and uncertainties that could result in the actual outcome being absolutely different from the results anticipated by the statements mentioned in the press release.Factors such as the development of general economic conditions affecting our business, future market conditions, our ability to maintain cost advantages, uncertainty with respect to earnings, corporate actions, client concentration, reduced demand, liability or damages in our service contracts, unusual catastrophic loss events, war, political instability, changes in government policies or laws, legal restrictions impacting our business, impact of pandemic, epidemic, any natural calamity and other factors that are naturally beyond our control, changes in the capital markets and other circumstances may cause the actual events or results to be materially different, from those anticipated by such statements. CleverTap does not make any representation or warranty, express or implied, as to the accuracy, completeness, or updated or revised status of such statements. Therefore, in no case whatsoever will CleverTap and its affiliate companies be liable to anyone for any decision made or action taken in conjunction.For more information:SONY SHETTYDirector, Communications, CleverTap+91 9820900036sony@clevertap.comASHMIT CHAUDHARYAssociate Consultant, Archetype+91 8850752121ashmit.chaudhary@archetype.co Copyright 2024 ACN Newswire via SeaPRwire.com.

SAN DIEGO, CA, Dec 3, 2024 - (ACN Newswire via SeaPRwire.com) - On November 19, 2024, General Atomics Aeronautical Systems, Inc. (GA-ASI) hosted its first Blue Magic Netherlands (BMN) event in Eindhoven, the Netherlands. Approximately 200 people attended the event that provided Dutch businesses with an opportunity to present their capabilities to GA-ASI and other companies interested in possible collaborations. GA-ASI was joined for the event by the Netherlands Ministry of Economic Affairs, the Netherlands Ministry of Defence, Lockheed Martin Ventures, Brainport Development, Brabant Development Agency (BOM), the Netherlands Industries for Defence & Security (NIDV), and SpaceNED.At this event, GA-ASI and its partners heard first-hand from Dutch companies about the important capabilities they are developing. The process started in July when GA-ASI put out an open invitation to Dutch businesses to apply for the opportunity to present innovative technologies at the November 19 event. Key areas of focus included Artificial Intelligence/Machine Learning, Autonomy, Advanced Materials, Sensors, Advanced Manufacturing, and Space. Close to 50 companies applied and after reviewing the applications, 15 businesses were selected to pitch their capabilities to an audience that included lightweight lattice structures, gas detection technologies, advanced battery and photonics applications, and several innovative unmanned system and AI applications, among many others."This event is where the rubber meets the road," said Brad Lunn, Managing Director-Strategic Finance at GA-ASI. "In addition to attracting many companies, we increased the areas of expertise and depth of knowledge from the presenting companies in order to provide research, development, and breakthrough innovations to support current and future missions by GA-ASI aircraft. We also wanted to give the companies an opportunity to pitch in front of other potential customers, partners, and investors."The first Blue Magic event held by GA-ASI was in 2019 in Belgium, with subsequent events held in 2020, 2021, and 2023. GA-ASI is delivering eight MQ-9A Remotely Piloted Aircraft to the Royal Netherlands Air Force (RNLAF).GA-ASI expects to announce technology partnerships stemming from the BMN event and intends to hold this event on an annual basis in the Netherlands.About GA-ASIGeneral Atomics Aeronautical Systems, Inc. (GA-ASI), an affiliate of General Atomics, is a leading designer and manufacturer of proven, reliable remotely piloted aircraft (RPA) systems, radars, and electro-optic and related mission systems, including the Predator® RPA series and the Lynx® Multi-mode Radar. With more than eight million flight hours, GA-ASI provides long-endurance, mission-capable aircraft with integrated sensor and data link systems required to deliver persistent flight that enables situational awareness and rapid strike. The company also produces a variety of ground control stations and sensor control/image analysis software, offers pilot training and support services, and develops meta-material antennas. For more information, visit www.ga-asi.com.Avenger, Lynx, Predator, Reaper, SeaGuardian, and SkyGuardian are registered trademarks of General Atomics Aeronautical Systems, Inc.Contact InformationGA-ASI Media Relationsasi-mediarelations@ga-asi.comSource: General Atomics Aeronautical Systems, Inc. Copyright 2024 ACN Newswire via SeaPRwire.com.

HONG KONG, Dec 3, 2024 - (ACN Newswire via SeaPRwire.com) - December 2, 2024, In the context of the Belt and Road Initiative, the first Belt and Road Golden Route Series Financial Promotion Event——the Kyrgyz Republic Ministry of Finance's promotional seminar and non-deal roadshow was successfully held today in Hong Kong. The event was jointly hosted by TF International Securities Group Limited ("TF International") and China CITIC Bank International Limited ("China CITIC Bank International"), attracting numerous international investors and financial industry leaders.The Kyrgyz Republic, as one of the earliest countries to support and engage in the Belt and Road Initiative, has seen increasingly close economic and trade relations with China. Recently, TF International signed a memorandum of understanding with the Kyrgyz Republic Ministry of Finance, becoming the first Hong Kong-based Chinese securities firm to establish an official partnership with the Kyrgyz Republic Ministry of Finance. The two parties work together to promote the RMB internationalization, support the real economy, facilitate high-quality development, and reinforce Hong Kong’s position as an international financial center. The event featured distinguished guests, including Mr. Amanbaev Umutzhan Mominovich, Deputy Minister of Finance of Kyrgyz Republic, Mr. Abdybapov Abdanbek Abdybapovich, Head of the Government Borrowing Department of Kyrgyz Republic, Mr. CHAN Ho Lim, Joseph, JP, Under Secretary for Financial Services and the Treasury of Hong Kong S.A.R., and Mr. ZOU Chuan, CEO of TF International, as well as Mr. Andy Siow, Senior Coverage Banker, DCM, at China CITIC Bank International. They shared insights into Kyrgyzstan’s development opportunities and investment prospects in the international financial market, discussing investment opportunities and key focus areas for mutually beneficial cooperation. In his opening speech, Mr. CHAN Ho Lim, Under Secretary for Financial Services and the Treasury of Hong Kong, remarked, "Hong Kong has firmly established itself as Asia’s leading international financial centre. Our core strengths include free flow of capital and information, a robust common law system, and a simple and low tax regime, and Hong Kong enjoys preferential access to Mainland China. All these position Hong Kong as the super-connector between China and international markets, which plays a key role in promoting RMB internationalization and advancing the Belt and Road Initiative. The Kyrgyz Republic is an important partner under the Belt and Road Initiative and is certainly Hong Kong’s important trading partner in Central Asia.” He also stated that, “I would like to express my gratitude to the Kyrgyz Republic Ministry of Finance and TF International and appreciate your commitment to fostering stronger ties between Central Asia and Hong Kong. We look forward to exploring potential future collaborations with the Kyrgyz Republic that will benefit our respective markets and promote partnerships among Belt and Road nations.” As of September 1, 2024, Renminbi (RMB) has been included in the list of official daily exchange rates published by Kyrgyzstan, alongside the US dollar, euro, Russian ruble, and Kazakh tenge. This move further strengthens economic and financial cooperation between the two countries. Mr. Amanbaev Umutzhan Mominovich, Deputy Minister of Finance of the Kyrgyz Republic, stated, "The inclusion of the RMB in the list of official daily exchange rates in Kyrgyzstan marks a new stage in the economic cooperation between the two countries. This not only provides greater convenience for international investors but also empowers the development of Kyrgyzstan's financial market. Through this promotional event, we hope to connect with more international investment institutions and jointly promote the sustainable development of the regional economy." Hong Kong, as the international financial center and the central city of the Guangdong-Hong Kong-Macao Greater Bay Area, plays an important bridging role in the Belt and Road Initiative, leveraging its diverse financing channels and close alignment with national strategies. Mr. ZOU Chuan, CEO of TF International, stated, "The Belt and Road Initiative offers significant opportunities for economic integration and development, enhancing trade across Asia, Europe, the Middle East, and beyond. As a gateway between China and the world, Hong Kong is a key hub for the internationalization of the Renminbi, facilitating its use in trade and investment, and supporting effective currency risk management for BRI projects. With ongoing economic expansion and the internationalization of the Renminbi, Hong Kong is well-positioned to emerge as the premier financing hub. As we explore upcoming opportunities, I encourage you to envision the transformative impact these initiatives can have on the Kyrgyz Republic’s development agenda and the broader economic landscape of Central Asia. Together, we can unlock new avenues for growth and collaboration." From December 3 to 6, 2024, TF International, in collaboration with China CITIC Bank International will join forces with the Kyrgyz Republic Ministry of Finance in hosting a series of non-deal roadshows in Shanghai and Beijing, further strengthening ties with the Chinese financial market. The success of today’s promotional seminar and non-deal roadshow in Hong Kong marks a new milestone in the economic cooperation between the two countries and injects fresh momentum into the high-quality development of the Belt and Road Initiative. Copyright 2024 ACN Newswire via SeaPRwire.com.

London, UK, Dec 2, 2024 - (ACN Newswire via SeaPRwire.com) - The 3rd edition of the London Climate Technology Show concluded last week, paving a vital roadmap towards fully decarbonising our planet through sustainable technologies. The event brought together policymakers, eco-technology leaders, industry professionals, and innovators, all unified in their call for an immediate shift to sustainable and green solutions to secure a better future for the planet.The two-day event opened on 27th November with an inspiring keynote by Felicity Burch, Executive Director of the Responsible Technology Adoption Unit at the Department for Science, Innovation, and Technology (DSIT), who spoke about AI Innovation in Clean Energy and the DSIT's Manchester Prize. Following her, Ing. Abigail Cutajar, CEO of the Climate Action Authority, talked about Pioneering the Surge Towards Climate and Energy Transitions.The conference unfolded over two dynamic days, featuring a packed agenda of insightful presentations and engaging panel discussions. It delved into actionable strategies for decarbonisation, advancements in AgriTech, the evolving carbon market, eco-funds, energy, CCS, built environment and other groundbreaking innovations in climate technology.Notable discussions highlighted the need for farmers to balance carbon stewardship with food production over the next few decades, the importance of consistent government policies to enable businesses to plan and innovate effectively, and the urgency of addressing digital and engineering skill shortages to ensure a successful green energy transition. Industry experts also called for common sustainability metrics to measure corporate efforts fairly, emphasized the value of collaboration over competition to accelerate the green transition, and underscored the need for farmers to access landscape-level data to enhance biodiversity.The exhibition hall featured groundbreaking innovations and solutions in sustainability and climate technology, including carbon capture and storage (CCS) from companies like CGI and Terra CO2 Technology, carbon management and accounting solutions by Greenly and Gaia Carbon Accounting, and emerging climate technologies from innovators such as Nabla Flow and Luna 9. Other exhibitors showcased AI-driven solutions, sustainable energy systems, and innovative carbon reduction technologies, presenting a comprehensive snapshot of the future of climate tech.#CTS24 also hosted interactive side events, including startup acceleration programs and hands-on workshops, providing participants with opportunities for learning, networking, and collaboration. These sessions empowered attendees to adopt transformative technologies and take decisive climate action.Attendee ExperiencesThe event received overwhelming positive feedback:Mark Haley, Co-founder of Cero3, shared, "We’re so proud to have unveiled our sustainable travel planner. The feedback and interest exceeded our expectations."Satyajit Mohanan, Projects and Business Development Coordinator at Cambridge Cleantech, remarked, "It was a pleasure to be part of this event. I met amazing people and look forward to the next edition."Dennis Chacko, Senior Sales Manager at the British Board of Agreement, shared his excitement over a unique sustainable pen: "Once used, you can plant it to grow something new—a powerful reminder of how everyday items can contribute to a greener future."As this successful edition concludes, the organisers are already planning for a bigger, more impactful 4th Edition, with expanded content and greater opportunities to drive meaningful change toward a sustainable future.For further information, please reach out to us at press@valiantandcompany.com. Copyright 2024 ACN Newswire via SeaPRwire.com.

SHENZHEN, CHINA, Dec 2, 2024 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce that on 2 December 2024, the Group through a wholly-owned subsidiary of the Company entered into an Exclusive Commercialization Agreement (the “Agreement”) with Atom Therapeutics Co., Ltd (hereinafter referred to as “Atom Therapeutics”, formerly named as “Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.”) of class 1 innovative drug ABP-671 for the treatment of gout and hyperuricemia (the “Product”). In accordance with the Agreement, the Group is entitled to an exclusive commercialization right of the Product in Mainland China, Hong Kong Special Administrative Region and Macao Special Administrative Region. The term of cooperation commences on the effective date of the Agreement and extends for ten years from the date the Product is first approved for market launch in Mainland China (the "Authorization Term"). Upon the expiration of the Authorization Term, it may be automatically renewed for an additional ten years, subject to specific conditions stipulated in the Agreement.ABP-671 is a class 1 innovative chemotherapeutic drug for the treatment of gout and hyperuricemia, currently in Phase 2b/3 clinical trials for gout in China and overseas. The Product reduces renal re-absorption of uric acid by inhibiting Urate Anion Transporter 1 (URAT1). The results of two completed phase 2 clinical trials demonstrated favorable efficacy and safety profiles across multiple dose groups (ranging from 1 mg to 12 mg) of ABP-671. The 2 mg once-daily dosage of the Product was proved to be as effective as, or even better than, benzbromarone or febuxostat (maximum dosage of 80mg). The reduction in uric acid levels was sustained throughout the 24-hour period, with no significant safety concerns identified. This product is anticipated to offer more effective and safer treatment alternatives for patients suffering from gout and hyperuricemia[1]. Multiple patents in regard to substance and use of the ABP-671 have been granted in China.Hyperuricemia is defined as a fasting blood uric acid level exceeding 420μmol/L (7.0 mg/dL) in adults on a normal purine diet on two separate days. The deposition of urate crystals in hyperuricemia patient results in arthritis, medically termed gout. Hyperuricemia and gout can cause acute and chronic inflammatory injury in articular cartilage, bone, kidney and vascular wall, which can lead to multiple organ damage of the heart, brain and kidney, etc. The data presented in the White Paper on Hyperuric Acid and Gout Trends in China (2021) indicates that, the incidence rate of hyperuricemia is 13.3%, with approximately 177 million hyperuricemia patients and the incidence rate of gout is 1.1% in general, with about 14.66 million gout patients in China. Frost & Sullivan indicates that, the number of people with hyperuricemia and gout in China will continue to increase in the future, reaching 240 million and 52.2 million respectively by 2030. Currently, the commonly used uric acid-lowering drugs in clinical practice in China are those which inhibit uric acid synthesis or promote uric acid excretion. Due to certain limitations in the efficacy and safety of the marketed uric acid-lowering drugs, such as causing renal failure, sudden cardiac death or severe liver toxicity. There is still an urgent need for effective and safe uric acid-lowering drugs among gout and hyperuricemia patients in China.ABP-671 is currently with the potential to be the promising and safe product for the treatment of gout and hyperuricemia. Through this collaboration, it fills the blank in the CMS's product portfolio of the treatment of gout. Gout and hyperuricemia are both rheumatic diseases and chronic metabolic diseases, which are highly consistent with the Group's strategic layout in the cardio-cerebrovascular/ gastroenterology business and the network resources of marketed products. If approved for marketing in the future, the Product will synergize with the Group’s marketed product Metoject (methotrexate injection) in rheumatology and with Elcitonin (elcatonin injection) in endocrinology and orthopedics, in terms of expert network and market resources. Based on the unmet clinical needs and the expected solid clinical data of the Product, the Group is looking forward to the smooth advancement of the clinical development of ABP-671, allowing patients with relevant indications to benefit from this innovative treatment sooner.About ATOM THERAPEUTICSAtom Therapeutics was founded in March 2012, focused on the research and development of innovative drugs with global commercial value and competitiveness in the metabolic and inflammatory area. Atom Therapeutics's main core team members come from the United States, with extensive experience in the research and development of innovative drugs. Atom Therapeutics has achieved remarkable development in the past few years. Atom Therapeutics's core product ABP-671 is under pivotal clinical stage for the treatment of chronic gout. Atom Therapeutics's another small molecule innovative drug named as ABP-745, used for indications in the field of anti-inflammatory immune indications. The Phase 1 clinical of ABP-745 exhibited outstanding pharmacokinetics and safety. The clinical trial is on the verge of entering Phase 2. For more information about Atom Therapeutics and its pipeline, please visit https://www.atombp.com/.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries. While strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology business, CMS independently operates its dermatology and medical aesthetics business, and ophthalmology business, aiming to gain leading positions in specialty therapeutic fields, whilst enhancing the scale and efficiency. At the same time, CMS has expanded its business territory to the Southeast Asian market, striving to become a "bridgehead" for global pharmaceutical companies to enter the Southeast Asian market, further escorting the sustainable and healthy development of the Group.Reference:1. The results of Phase 2 clinical trials was published and can be found at: https://www.atombp.com/2023/03/01/atom-bioscience-announces-positive-results-of-phase-2a-china-clinical-trial-of-its-urat1-inhibitor-for-chronic-gout/CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsWebsite: https://web.cms.net.cn/en/home/Source: China Medical System Holdings Ltd. Copyright 2024 ACN Newswire via SeaPRwire.com.

SHANGHAI, Dec 2, 2024 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that Department of Health of the Government of the Hong Kong Special Administrative Region, China, has accepted Everest’s New Drug Application (NDA) for VELSIPITY(R) (etrasimod) for the treatment of adult patients with moderately to severely active ulcerative colitis.  VELSIPITY(R) is an effective and convenient, once-daily, oral treatment for patients with moderately-to-severely active UC that has already been approved in the U.S. and E.U., and other countries, by Everest’s licensing partner, Pfizer. In Everest territories, the Pharmaceutical Administration Bureau of the Macau Special Administrative Region, China has approved the NDA for VELSIPITY(R) in April of this year and was implemented in the Guangdong-Hong Kong-Macau Greater Bay Area this October through the "Hong Kong and Macau Medicine and Equipment Connect" policy."Autoimmune disease is a core focus and a significant growth driver for our company. The number of UC patients in China is projected to double from 2019 to 2030 to approximately one million, highlighting the urgent need for novel treatments." said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “Previously, VELSIPITY(R) has already been approved in Macau, China, and was implemented in the Greater Bay Area through the connect policy. The company also plans to submit the NDA for approval by China’s National Medical Products Administration (NMPA) this year, with the aim of benefiting more Chinese patients as soon as possible."" This is an important advancement for etrasimod, bringing hope to patients in Hong Kong, China. This new-generation S1P receptor modulator is an oral, once-daily treatment that can provide patients with a chance for corticosteroid-free remission, mucosal healing, and rapid symptom relief, " said Prof. Wu Kaichun with the First Affiliated Hospital of AFMU who is the principal investigator for etrasimod’s Asia clinical trial. “We hope China and other Asian countries can obtain approvals as soon as possible to benefit more patients."The acceptance of the NDA was based on results from the ELEVATE UC Phase 3 registrational program (ELEVATE UC 52 and ELEVATE UC 12) that evaluated the safety and efficacy of etrasimod 2 mg once-daily on clinical remission in UC patients with moderately to severely active UC who had previously failed or were intolerant to at least one conventional, biologic, or Janus kinase (JAK) inhibitor therapy. Nearly two-thirds of patients in ELEVATE UC 52 and ELEVATE UC 12 were naïve to biologic or JAK inhibitor therapy, and these studies were also the only studies for advanced therapies for ulcerative colitis to include patients with isolated proctitis. Both studies achieved all primary and key secondary efficacy endpoints, with a favorable safety profile consistent with previous studies of etrasimod.Everest conducted a multicenter, randomized, double-blind and placebo-controlled Phase 3 trial of etrasimod in Asian countries, including mainland China, China Taiwan and South Korea. This is the largest Phase 3 trial of moderately-to-severely active ulcerative colitis in Asia completed to date, with 340 eligible subjects randomized to treatment with etrasimod or placebo. The previously announced results of the induction period indicate that the clinical remission rate for patients treated with etrasimod 2mg was 25.0%, compared to 5.4% for those treated with placebo (difference 20.4%, p<0.0001). Compared to the placebo group, patients treated with etrasimod demonstrated significant clinical and statistically significant improvements in all key secondary endpoints. Subsequently, the topline results from maintenance period released in July of this year confirmed that after 40 weeks of treatment, etrasimod demonstrated significant clinical and statistical improvements over placebo in the primary and all key secondary endpoints (p<0.0001), and other secondary endpoints (including mucosal healing and endoscopic normalization, both p<0.0001). The safety profile of etrasimod was consistent with previous studies, with no new safety signals observed. The results of the maintenance period will be released at an international academic conference.About VELSIPITY(R) (etrasimod)VELSIPITY(R) is a once-daily, oral, sphingosine 1-phosphate (S1P) receptor modulator that selectively binds with S1P receptor subtypes 1, 4, and 5. Regulatory approvals have been granted in US, EU, Canada, Australia, Singapore, UK, Switzerland, Israel and Macau, China for VELSIPITY(R) in ulcerative colitis.About Everest MedicinesEverest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company’s core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders. For more information, please visit its website at www.everestmedicines.com.Forward-Looking Statements:This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law. Copyright 2024 ACN Newswire via SeaPRwire.com.

深圳, 2024年12月2日 - (亞太商訊 via SeaPRwire.com) - 康哲藥業控股有限公司（以下簡稱「康哲藥業」）欣然宣佈，於2024年12月2日，通過其全資附屬公司與杭州新元素藥業有限公司（以下稱「新元素藥業」，曾用名「江蘇新元素醫藥科技有限公司」）就治療痛風及高尿酸血症的1類新藥ABP-671（「產品」）簽訂獨家商業化協議（「協議」）。根據協議，康哲藥業獲得產品在中國大陸、香港特別行政區及澳門特別行政區的獨家商業化權利。合作期限開始於協議生效之日，自產品首次在中國大陸獲批上市起擁有十年的授權期限（「授權期限」）。授權期限屆滿後，根據協議約定的特定條件，授權期限可自動續期十年。ABP-671是用於治療痛風及高尿酸血症的化藥1類創新藥，目前正分別在中國和境外開展關於痛風的2b/3期臨床試驗，產品通過抑制尿酸鹽轉運蛋白1（URAT1），降低腎臟對尿酸的重吸收。在已經完成的兩項2期臨床試驗結果顯示，ABP-671多個劑量組（1mg至12mg）表現出良好的藥效和安全性。該產品2mg每天單次給藥，其藥效可能相當於或優於苯溴馬隆和非布司他最高劑量80mg的藥效。尿酸下降可維持全天候24小時，沒有出現嚴重的安全性問題。產品有望為痛風及高尿酸血症患者帶來療效更優、安全性更高的治療選擇[1]。與ABP-671相關的化合物和用途方面的多個專利已在中國獲得授權。高尿酸血症是指成人在正常嘌呤飲食情況下，非同日2次空腹血尿酸水平超過420μmol/L (7.0mg/dL)。高尿酸血症患者出現尿酸鹽晶體沉積，導致痛風性關節炎，稱為痛風。高尿酸血症及痛風可引起關節軟骨、骨質、腎臟以及血管壁等急慢性炎症損傷，導致心、腦、腎等多器官損害。《2021中國高尿酸及痛風趨勢白皮書》數據顯示，我國高尿酸血症的總體的患病率為13.3%，高尿酸血症患病人數約1.77億人，痛風總體發病率為1.1%，患病人數約為1,466萬。據弗若斯特沙利文分析，未來中國高尿酸血症和痛風患病人數會持續增加，將在2030年分別達到2.4億人、5,220萬人。目前我國臨床上常用的降尿酸藥物主要包括抑制尿酸合成和促進尿酸排泄兩類，由於已上市降尿酸藥物在療效和安全性上仍存在一定的局限性，如導致腎衰竭、心臟猝死或嚴重肝臟毒性等。中國痛風及高尿酸血症患者對高效安全的降尿酸藥物仍然有迫切的需求。ABP-671是當前痛風及高尿酸血症治療中潛在療效優、安全性好的產品。通過本次合作引進，填補了康哲藥業痛風治療產品的空白。痛風及高尿酸血症既屬於風濕疾病又屬於慢性代謝性疾病，與康哲藥業心腦血管/消化業務的戰略佈局，以及在售品種的網絡資源高度契合。ABP-671如未來獲批上市，在風濕免疫科可與在售產品美泰彤（甲氨蝶呤注射液），在內分泌科和骨科可與益蓋寧（依降鈣素注射液）在專家網絡與市場資源方面協同。基於未滿足的臨床需求和產品預期扎實的臨床數據，期待ABP-671的臨床開發工作順利推進，使相關適應症患者儘快從創新療法中獲益。關於新元素藥業新元素藥業創辦於2012年3月，專注於代謝和炎症領域疾病中具有全球商業價值和全球競爭力的創新藥的研發。新元素藥業主要核心團隊人員來自美國，具有廣泛的創新藥物的研發經驗，過去幾年新元素藥業取得了顯著的發展成果。其核心產品ABP-671正處於後期臨床研發階段，用於治療慢性痛風；另一個小分子創新藥物ABP-745用於抗炎自免領域適應症，已完成1期臨床，表現出良好的PK和安全性，即將進入2期臨床。有關新元素藥業及其產品的更多信息，請訪問其官方網站：https://www.atombp.com/。關於康哲藥業康哲藥業是一家鏈接醫藥創新與商業化，把控產品全生命週期管理的開放式平臺型企業，致力於提供有競爭力的產品和服務，滿足尚未滿足的醫療需求。康哲藥業專注於全球首創（FIC）及同類最優（BIC）的創新產品，並高效推進創新產品臨床研究開發和商業化進程，賦能科研成果向診療實踐的持續轉化，造福患者。康哲藥業聚焦專科領域，擁有被驗證的商業化能力，廣泛的渠道覆蓋和多疾病領域專家資源，核心在售產品已獲領先的學術與市場地位。康哲藥業圍繞優勢專科領域不斷縱深發展，以鞏固心腦血管/消化業務競爭力，並將皮膚醫美、眼科業務獨立運營，培育專科小領域的大龍頭，提升專科規模效率。同時業務版圖拓展至東南亞市場，著力成為全球藥企進軍東南亞市場的「橋頭堡」，助力康哲藥業高質量持續健康發展。參考文獻：1.產品2期臨床試驗結果已發佈，詳情如下：https://www.atombp.com/2023/03/01/atom-bioscience-announces-positive-results-of-phase-2a-china-clinical-trial-of-its-urat1-inhibitor-for-chronic-gout/康哲藥業免責與前瞻性聲明本新聞無意向您做任何產品的推廣，非廣告用途。本新聞不對任何藥品和醫療器械和/或適應症作推薦。若您想瞭解具體疾病診療信息，請遵從醫生或其他醫療衛生專業人士的意見或指導。醫療衛生專業人士作出的任何與治療有關的決定應根據患者的具體情況並遵照藥品說明書。由康哲藥業編制的此新聞不構成購買或認購任何證券的任何要約或邀請，不形成任何合約或任何其他約束性承諾的依據或加以依賴。本新聞由康哲藥業根據其認為可靠之資料及數據編制，但康哲藥業並無進行任何說明或保證、明述或暗示，或其他表述，對本新聞內容的真實性、準確性、完整性、公平性及合理性不應加以依賴。本新聞中討論的若干事宜可能包含涉及康哲藥業的市場機會及業務前景的陳述，該等陳述分別或統稱為前瞻性聲明。該等前瞻性聲明並非對未來表現的保證，存在已知及未知的風險、不明朗性及難以預知的假設。康哲藥業並不採納本新聞包含的第三方所做的任何前瞻性聲明及預測，康哲藥業對該等第三方聲明及預測不承擔責任。 Copyright 2024 亞太商訊 via SeaPRwire.com.

香港, 2024年12月3日 - (亞太商訊 via SeaPRwire.com) - 2024年12月2日，在「一帶一路」倡議的背景下，由天風國際證券集團有限公司（以下簡稱「天風國際」）與中信銀行(國際)有限公司（以下簡稱「信銀國際」）聯合主辦的首場「一帶一路」黃金線系列金融推介會——吉爾吉斯斯坦國家財政部推介會暨非交易性路演於今日在香港圓滿舉行。本次活動吸引了眾多國際投資機構及金融行業領袖出席。吉爾吉斯斯坦作為最早支持和參與「一帶一路」倡議的國家之一，近年來與中國的經貿合作關係日益密切。近期，天風國際與吉爾吉斯斯坦國家財政部簽訂合作備忘錄，成為首家與吉爾吉斯斯坦國家財政部建立合作關係的駐港中資券商。雙方將就共同推動人民幣國際化願景，服務實體經濟，助力高質量發展，為維持並進一步鞏固香港作為國際金融中心的地位，展開更廣泛的合作。本次活動邀請了多位重量級嘉賓，包括吉爾吉斯斯坦國家財政部副部長Amanbaev Umutzhan Mominovich先生、政府借貸部主任Abdybapov Abdanbek Abdybapovich先生、香港特別行政區政府財經事務及庫務局副局長陳浩濂太平紳士，以及天風國際行政總裁鄒傳先生和信銀國際高級董事、債券資本市場、財資及環球市場Andy Siow先生。會上，嘉賓們分享了吉爾吉斯斯坦在參與國際金融市場的發展機遇與其投資前景，共同探討了雙方互利共贏的合作著力點。陳浩濂副局長在致辭中表示：「香港作為全球主要國際金融中心，具備資本與信息的自由流動、穩健的普通法制度以及單一稅制等核心優勢，同時香港與中國內地市場聯繫緊密，在促進人民幣國際化和推動『一帶一路』倡議中發揮著關鍵作用。而吉爾吉斯斯坦作為『一帶一路』倡議下的重要合作夥伴，毫無疑問，也是香港在中亞地區的重要貿易夥伴。感謝天風國際的精心組織和吉爾吉斯斯坦代表團的到訪，今天我們齊聚一堂，探討如何進一步加强中亞與香港之間的經濟合作。我們期待未來與吉爾吉斯斯坦的合作將為兩國經濟增長注入新的動力，推動『一帶一路』國家之間的多層次合作，進一步促進區域經濟的可持續發展。」自2024年9月1日起，人民幣已正式列入吉爾吉斯斯坦官方每日公佈匯率的貨幣名單，與美元、歐元、俄羅斯盧布和哈薩克斯坦堅戈一起，成為吉爾吉斯斯坦每日公佈匯率的貨幣，這一舉措進一步深化了兩國在經濟與金融領域的合作。吉爾吉斯斯坦國家財政部副部長Amanbaev Umutzhan Mominovich先生在會上表示：「人民幣成功納入吉爾吉斯斯坦官方每日公佈匯率的貨幣名單，標誌著兩國經濟合作進入了新的階段。這不僅為國際投資者提供了更多便利，也為吉爾吉斯斯坦的金融市場發展賦能。我們希望通過此次推介會，與更多國際投資機構建立聯繫，共同推動區域經濟的可持續發展。」香港作為國際金融中心，同時也是粵港澳大灣區的核心城市，憑藉多樣的融資渠道和與國家戰略的深度對接，在「一帶一路」倡議中發揮了重要的橋梁作用。作為此次活動的聯合主辦方之一，天風國際行政總裁鄒傳先生在致辭中提到：「『一帶一路』倡議為經濟一體化和發展提供了巨大機遇，推動亞歐、中東乃至更廣泛地區的貿易往來。香港作為中國市場聯通世界的重要窗口，同時也是人民幣國際化的關鍵樞紐，促進人民幣在貿易和投資中的使用，支持『一帶一路』項目的融資與匯率風險管理。隨著人民幣國際化的推進，香港正穩步成為全球領先的融資中心。在探索未來機遇的同時，期待今日的活動與市場洞察的深入分享，對吉爾吉斯斯坦發展進程以及中亞經濟帶來積極、深遠的影響。」後續，天風國際聯合信銀國際將陪同吉爾吉斯斯坦國家財政部於12月3日至6日期間，陸續在上海和北京繼續舉辦系列非交易性路演活動，進一步深化吉爾吉斯斯坦與中國金融市場的聯繫。此次香港推介會的成功舉辦標誌著兩國在經濟領域合作邁向新高度，為「一帶一路」倡議的高質量發展注入了新動能。 Copyright 2024 亞太商訊 via SeaPRwire.com.

上海, 2024年12月2日 - (亞太商訊 via SeaPRwire.com) -雲頂新耀（HKEX 1952.HK）是一家專注于創新藥研發、臨床開發、製造和商業化的生物製藥公司，今日宣佈中國香港衛生署已正式受理伊曲莫德（VELSIPITY(R)）用於治療中重度活動性潰瘍性結腸炎成人患者的新藥上市許可申請（NDA）。伊曲莫德是一款每日一次口服的一線先進療法，不僅使用方便、療效佳，而且具有良好的安全性特征。伊曲莫德已於去年10月和今年2月先後在美國和歐盟獲得新藥上市批准，同時，伊曲莫德也於今年4月獲得中國澳門特別行政區藥物監督管理局批准上市，並於今年10月通過「港澳藥械通」政策在粵港澳大灣區落地。雲頂新耀首席執行官羅永慶表示：「我們非常高興看到伊曲莫德的新藥上市許可申請在中國香港獲得正式受理。自身免疫性疾病是我們的重點關注領域和重要價值的潛在增長動力。到2030年，中國的潰瘍性結腸炎患者人數預計將達到約100萬人，超過2019年患者人數的一倍以上，存在迫切且巨大的未被滿足的臨床需求。伊曲莫德已在中國澳門獲批，並通過「港澳藥械通」政策率先在粵港澳大灣區落地。今年我們預計也將在中國大陸地區遞交伊曲莫德的新藥上市許可申請。期待伊曲莫德在更多地區獲批，進一步擴大可及性，造福廣大患者。」伊曲莫德亞太臨床試驗牽頭研究者、世界胃腸病學會執行理事、亞太消化學會副主席、中國人民解放軍空軍軍醫大學附屬西京醫院吳開春教授表示：「祝賀伊曲莫德取得的這一新進展，為中國香港的患者帶來了希望。伊曲莫德具有良好的獲益-風險特征，這種新一代S1P受體調節劑通過每日一次口服的治療方案，可快速起效，並達到無激素緩解、黏膜癒合，可為中重度活動性潰瘍性結腸炎成人患者提供先進的治療選擇。我們期待伊曲莫德在大中華區及其他亞洲國家早日獲批，為患者帶來福音。」伊曲莫德的申請是基於ELEVATE UC III期註冊研究（ELEVATE UC 52和ELEVATE UC 12）的結果，該研究旨在評價既往對至少一種常規治療、生物製劑或Janus激酶（JAK）抑制劑治療失敗或不耐受的中重度活動性潰瘍性結腸炎患者，每日一次服用2mg 伊曲莫德的安全性和療效。在ELEVATE UC 52和ELEVATE UC 12中，納入了一半以上嚴重活動性潰瘍性結腸炎患者（mMS≥7），並有近三分之一患者曾接受過生物製劑或JAK抑制劑治療。伊曲莫德的UC研究也是迄今唯一納入了孤立性直腸炎患者的UC研究。這兩項隨機、雙盲、安慰劑對照研究均達到了所有主要和關鍵次要終點，安全性特征與既往研究一致。在ELEVATE UC 52研究中，第12周時，接受伊曲莫德治療的患者臨床緩解率為27.0%（安慰劑組7.0%, 差異20.0%，P<0.001）；第52周時，接受伊曲莫德治療的患者臨床緩解率為32.0%（安慰劑組7.0%，差異26.0%，P<0.001）。在ELEVATE UC 12研究中，接受伊曲莫德治療的患者12周臨床緩解率為26.0%（安慰劑組15.0%，差異11.0%，P<0.05）。在這兩項研究中，伊曲莫德治療組所有關鍵性次要終點均達到統計學意義的顯著改善，包括第12周和52周的臨床應答、內鏡改善和組織學內鏡下黏膜改善終點以及第52周的無激素緩解和持續臨床緩解。伊曲莫德的安全性與之前的研究一致，最常見的不良反應是貧血和頭痛。雲頂新耀在亞洲地區（包括中國大陸、中國台灣和韓國）開展的伊曲莫德多中心、隨機、雙盲、安慰劑對照III期研究，是迄今為止完成的最大規模的亞洲中重度潰瘍性結腸炎的III期註冊臨床研究，總計 340名中重度潰瘍性結腸炎患者隨機接受伊曲莫德或安慰劑治療。此前公佈的誘導期結果顯示，伊曲莫德2mg治療的患者的臨床緩解率為25.0%，安慰劑治療的患者為5.4%（差值20.4%，p<0.0001）。與安慰劑組相比，伊曲莫德治療的患者所有關鍵次要終點均有顯著的臨床意義和統計學意義的改善。隨後，今年7月份公佈的維持期頂線結果證實，在經過40周的維持期治療後，伊曲 莫德組與安慰劑組相比，主要終點和所有關鍵次要終點均具有顯著的臨床意義和統計學意義（p<0.0001）的改善，其他包括黏膜癒合、內鏡恢復正常等的次要終點也均達到具有顯著臨床意義和統計學意義（p<0.0001）的改善。維持期治療顯示了伊曲莫德良好的安全性，安全性資料與已知特征一致，沒有觀察到新的安全性信號。維持期的研究結果將在近期的國際學術會議發佈。關於伊曲莫德（VELSIPITY(R), etrasimod）伊曲莫德（VELSIPITY(R)，etrasimod）是一種每日一次口服的高選擇性鞘氨醇-1-磷酸（S1P）受體調節劑，採用優化的藥理學設計，與S1P受體1、4和5結合。伊曲莫德目前已在美國、歐盟、加拿大、澳大利亞、英國、瑞士、以色列以及中國澳門和新加坡獲得新藥上市批准。關於雲頂新耀雲頂新耀是一家專注于創新藥和疫苗研發、臨床開發、製造和商業化的生物製藥公司，致力於滿足亞洲市場尚未滿足的醫療需求。雲頂新耀的管理團隊在中國及全球領先製藥企業從事過高質量研發、臨床開發、藥政事務、化學製造與控制（CMC）、業務發展和商業化運營，擁有深厚的專長和豐富的經驗。雲頂新耀已打造多款疾病首創或者同類最佳的藥物組合，公司的治療領域包括腎科疾病、感染性和傳染性疾病、自身免疫性疾病。有關更多信息，請訪問公司網站：www.everestmedicines.com。前瞻性聲明本新聞稿所發佈的信息中可能會包含某些前瞻性表述，乃基於本公司或管理層在做出表述時對公司業務運營情況及財務狀況的現有看法、相信、和現有預期，可能會使用「將」、「預期」、「預測」、「期望」、「打算」、「計畫」、「相信」、「預估」、「確信」及其他類似詞語進行表述。這些前瞻性表述並非對未來業績的保證，會受到風險、不確定性及其他因素的影響，有些乃超出本公司的控制範圍，難以預計。因此，受我們的業務、競爭環境、政治、經濟、法律和社會情況的未來變化及發展等各種因素及假設的影響，實際結果可能會與前瞻性表述所含資料有較大差別。本公司及各附屬公司、各位董事、管理人員、顧問及代理未曾且概不承擔更新該稿件所載前瞻性表述以反映在本新聞稿發布日後最新信息、未來項目或情形的任何義務，除非法律要求。 Copyright 2024 亞太商訊 via SeaPRwire.com.

Key Financial Performance Highlights for Q1FY2025:Group’s total revenue for the quarter is RM40.2 million, contributed primarily by key clients in the e-mobility and energy storage segment, supplemented by the electronics segment.Recorded PAT of RM4.1million for the quarter under review.GP, PBT, PAT, and PATAMI margins remain in the double-digit levels at 18.2%, 10.9%, 10.2% and 11.9%, respectively due to continued cost discipline.BANGI, Malaysia, Nov 27, 2024 - (ACN Newswire via SeaPRwire.com) - Technology leader in providing turnkey, intelligent manufacturing automation solutions, GENETEC TECHNOLOGY BERHAD (“Genetec” or the “Company”), announced its financial results for the first quarter of its new financial year (“Q1FY2025). Despite the lower Year-on-Year (“YoY”) revenue, Genetec showcases its resilience with the continued profitability and high-double digit margins.The Company recorded revenue of RM40.2 million and gross profit (“GP”) of RM7.3 million for its Q1FY2025 ending 30 September 2024. It also reported profit before tax (“PBT”) of RM4.4 million, profit after tax (“PAT”) of RM4.1 million and profit after tax and minority interest (PATAMI) of RM4.8 million. Genetec continues to maintain double-digit margins for its GP, PBT, PAT and PATAMI of 18.2%, 10.9%, 10.2% and 11.9%, respectively.Genetec acknowledged that the last quarter has been challenging for the business which it believes was mainly attributed to policy uncertainties from the client’s operating markets. With the conclusion of the U.S. Presidential election and European policy developments, particularly on inflation, import tariffs, and decarbonisation, there is a sense of relief and clarity, and companies are moving forward with their capital expenditure with greater certainty.The Company, leveraging its expertise in customised automation technology and project execution, continue to work closely with its clients to deliver tailored solutions aimed at enhancing manufacturing automation, improving efficiency and increasing production yield for its clients. With its strong track record, Genetec is confident in its ability to continue to build trust and secure recurring business from its clients. Its high client retention rate stands as a testament to its exceptional performance and has been a key factor in the Company’s success. This strong foundation enables the Company to broaden its scope and product offerings with other divisions within the organisation of its existing clients to grow revenue over the long-term. At the same time, the Company’s business development team continue to explore new opportunities in new markets and industries, leveraging on its extensive experience and proven success working with leading international and reputable clients.Genetec’s Battery Energy Storage System (“BESS”) business is slowly gaining traction as it executes smaller-scale but strategically significant projects in both domestic and international markets. The Company remains confident that its execution capabilities and international track record will position Genetec favourably. Market developments such as the government’s recently announced Corporate Renewable Energy Supply Scheme (CRESS) through interest in pairing BESS technology with solar projects, will also support demand for BESS moving forward, and is a step in achieving 70 percent renewable energy in the capacity mix by 2050[1].Moving forward, Genetec remains committed to its strategy and focus on operational efficiency, strict cost management. With its low gearing levels and recent sale of subsidiary CLT Engineering Sdn Bhd to add to its already strong cash position, Genetec is positioning itself to ramp up operations in the coming months.About Genetec Technology BerhadGenetec Technology Berhad is a technology leader in providing customised full turnkey smart factory automation manufacturing lines. It is a public company listed on the Main Market of Bursa Malaysia Securities Berhad (Stock code: 0104). Its principal business focus is in the provision of high-quality, responsive and cost-effective designs, as well as the manufacturing of automated industrial systems, equipment and value-added services for its global customers in the Electric Vehicle (EV), Energy Storage, Automotive, Hard Disk Drive (HDD), Consumer Goods and Healthcare sectors.For more information please visit: https://genetec.net/.Issued by: Narro Communications on behalf of Genetec Technology Berhad[1] Source: Suruhanjaya Tenaga – Guidelines for CRESS Copyright 2024 ACN Newswire via SeaPRwire.com.

Vancouver, British Columbia--(ACN Newswire via SeaPRwire.com - November 28, 2024) - Military Metals Corp. (CSE: MILI) (OTCQB: MILIF) (FSE: QN90) (the "Company" or "MILI") is pleased to report that it has completed additional staking of claims surrounding the Last Chance antimony-gold property, located in Nye County, Nevada, just over 70km north of the town of Tonapah and 12km due west of Kinross' Round Mountain gold mine. The Company recently entered into a letter of intent to acquire the Last Chance antimony-gold property. Please refer to the Company's news release dated November 14, 2024, for additional details about the Last Chance property.Scott Eldridge, Chief Executive Officer of the Company, commented, "Antimony prices have now risen to $38,000 USD per tonne, making antimony the top performing commodity thus far for 2024. China's export restriction that came into play September 15, 2024, has created a supply crunch that has magnified the need for domestic development of defense sector metals. This additional staking solidifies complete coverage of what we believe is the entire mineralized system surrounding the Last Chance antimony-gold property."Location map, Last Chance PropertyTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/10818/231755_11f4bf32b4999b42_001full.jpgHistorical antimony-gold occurrences and a solitary shaft where limited historical production is recorded occur within a sequence of Paleozoic carbonates and Lower Mesozoic metamorphosed shales and carbonates; A series of ultramafic dykes as well as younger felsic intrusives and extrusives cut this sequence at several locations. Mineralization is structurally controlled, with folding, faulting and quartz veining seen throughout the metamorphosed sedimentary sequence at several locations across the property.A fence of claims was staked surrounding the Last Chance property to ensure that additional ground considered potentially prospective remains available to the Company when it begins its first field campaign scheduled for Q2/2025.The technical contents of this release were reviewed and approved by Avrom E. Howard, MSc, PGeo, geological consultant to Military Metals and a qualified person as defined by NI 43-101.About Military Metals Corp. The Company is a British Columbia-based mineral exploration company that is primarily engaged in the acquisition, exploration and development of mineral properties with a focus on antimony.ON BEHALF OF THE BOARD of DIRECTORSFor more information, please contact:Scott EldridgeCEO and Directorscott@militarymetalscorp.comFor enquiries, please call 604-722-5381 or 604-537-7556This news release contains "forward-looking information". Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-Looking information in this news release includes statements related to the completion of a binding agreement and closing of the acquisition of the Last Chance Gold Property, as well as future plans for exploration activities, and assumptions related to the continuation of the global demand for antimony. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this news release. These include meeting the conditions to close the acquisition of the Last Chance Gold Property, geopolitical developments related to the supply of antimony, the continued use of antimony and availability of alternatives, availability of capital and labour in respect of the properties that are the subjects of this news release, the results of any future exploration activities, which cannot be guaranteed, and such other factors as may impact both and any future activities in respect of the properties. Additional risk factors can also be found in the Company's public filings under the Company's SEDAR+ profile at www.sedarplus.ca. Forward-Looking statements contained herein are made as of the date of this news release and the Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward looking statements if circumstances, management's estimates or opinions should change, except as required by securities legislation. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements.The Canadian Securities Exchange has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/231755 Copyright 2024 ACN Newswire via SeaPRwire.com.

SHANGHAI, Nov 30, 2024 - (ACN Newswire via SeaPRwire.com) - Hua Medicine (the “Company”, HKEx stock code: 2552) announced today that the Company has successfully completed a Phase I clinical trial on its 2nd generation GKA candidate in U.S. at the 9th China BioMed Innovation and Investment Conference (CBIIC).The Phase Ia clinical trial of the second-generation GKA (HM-002-1005) was conducted in the United States in 40 subjects with Type 2 diabetes (T2D). This trial was randomized, double-blind, placebo-controlled, single-dose, focusing on safety, tolerability, and pharmacokinetics. The second-generation GKA is a novel molecular entity with optimized physicochemical properties, holding new patents, and serving as the prodrug of dorzagliatin (HMS5552). This study designed for once-daily oral administration. Its aim is to extend the drug's action duration in the body through sustained-release technology, enhance patient compliance, and prolong the stimulation of GLP-1 secretion in the intestines.The Single Ascending Dose (SAD) study demonstrates that HM-002-1005 tablets can be rapidly converted to HMS5552 in the human body, with minimal exposure level of prodrug in both blood and urine. The t1/2 (biological half-life) after a single dose of HM-002-1005 tablets was prolonged compared to dorzagliatin tablets. The Cmax of HMS5552 in plasma after a 184.5mg single dose is comparable to the plasma concentration of HMS5552 after a 75mg single dose of dorzagliatin tablet; likewise, the daily AUC of HMS5552 in plasma after a single dose of HM-002-1005 tablets is comparable to the exposure level of HMS5552 after a 75mg BID dose of dorzagliatin tablets. The research indicates that HM-002-1005 tablets are near-completely converted to HMS5552 in human, and its pharmacokinetic characteristics support for once-daily oral administration. The development of HM-002-1005 tablets not only contributes to enhancing patient medication adherence and effectively control blood glucose levels within 24 hours; meanwhile, it also offers the opportunity to explore the Maximum Tolerated Dose above 150mg daily to achieve better efficacy. The 75 mg BID dose regiment was developed under the concept of Minimum Therapeutic Effective Dose in Chinese T2D patients who suffered from an impairment of insulin secretion and significant reduction of early phase insulin. The different disease characters of T2D with obesity in western patient population would benefit dorzagliatin from its effects on GLP-1 secretion and improvement of insulin sensitivity.With the confirmation that the exposure level of HM-002-1005 tablets at 184.5mg is comparable to dorzagliatin tablets at 75mg (BID), we will further optimize the dosage form followed by a Multiple Ascending Dose (MAD) clinical development of the 2nd generation GKA in China and the United States.Dr. Li CHEN, founder and CEO of Hua Medicine, stated, “Hua Medicine has always been committed to treating Type 2 diabetes at its root cause by restoring patients’ ability to autonomously regulate blood glucose levels. Over the course of a decade, the Company has selected dosing and clinical research protocols that are safe and effective for the majority of Chinese diabetes patients, leading to the successful development of GKA and the clinical application of dorzagliatin. Building on this foundation, the Company will undergo a strategic upgrade by further exploring the therapeutic potential of GKA, enriching its product pipeline and seeking partners both domestically and internationally, in order to benefit a broader range of patients, expand into global markets, and effectively establish the brand identity of GKA medications while maximizing the commercial potential of our global first-in-class drugs.”About Hua MedicineHua Medicine (The “Company”) is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (Dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment.For more informationHua MedicineWebsite: www.huamedicine.comInvestorsE-mail: ir@huamedicine.comMediaE-mail: pr@huamedicine.com Copyright 2024 ACN Newswire via SeaPRwire.com.

SHANGHAI, Nov 30, 2024 - (ACN Newswire via SeaPRwire.com) - Hua Medicine (the “Company”, HKEx stock code: 2552) announced today that the Company has successfully completed its SENSITIZE study on the mechanism by which dorzagliatin improves the β-cell glucose sensitivity at the 9th China BioMed Innovation and Investment Conference (CBIIC).The SENSITIZE study was initiated by Professor Juliana Chan, an international endocrinology specialist at The Chinese University of Hong Kong, as the lead researcher. It is the first clinical study in Asian populations to evaluate the impact of GKA on β-cell glucose sensitivity in the populations with varying degrees of impaired glucose tolerance using the technology of hyperglycemic clamp. The study aims to explore the impairment of glucokinase (GK) function and clinical characteristics in different types of glucose dysregulation, providing new scientific evidence on the pathophysiology of Asian Type 2 diabetes and the central role of GK in blood glucose regulation.The SENSITIZE 2 study results announced at CBIIC demonstrate that a single dose of dorzagliatin restores GK enzyme activity, significantly improving the second-phase insulin secretion and β-cell glucose sensitivity in individuals with impaired glucose tolerance (IGT) in hyperglycemic clamp study. In addition, the SENSITIZE 1 study previously reported at the 2022 ADA annual meeting showed that dorzagliatin directly restores the activity of GK mutants, leading to significant improvements in the second-phase insulin secretion and β-cell glucose sensitivity in patients with glucokinase monogenic diabetes (GCK-MODY or MODY-2), and significantly enhance basal insulin secretion in newly diagnosed type 2 diabetes patients.Hua Medicine will continue to investigate β-cell glucose sensitivity improvement and incretin effect in response of repeated dose of dorzagliatin in individuals with intermediate hyperglycemia (IH) and Type 2 diabetes, in order to establish personalized intervention and treatment management plans for prediabetic and Type 2 diabetes patients.About Hua MedicineHua Medicine (The “Company”) is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (Dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment.For more informationHua MedicineWebsite: www.huamedicine.comInvestorsE-mail: ir@huamedicine.comMediaE-mail: pr@huamedicine.com Copyright 2024 ACN Newswire via SeaPRwire.com.

香港, 2024年11月30日 - (亞太商訊 via SeaPRwire.com) - 華領醫藥（「公司」，香港聯交所股份代號：2552.HK）今天在第九屆中國醫藥創新與投資大會（The China BioMed Innovation and Investment Conference，以下簡稱CBIIC）上宣佈，已經成功完成在美國開展的第二代葡萄糖激酶激活劑（GKA）的Ia臨床研究。第二代GKA（HM-002-1005）Ia臨床試驗是在美國40例2型糖尿病（T2D）受試者中進行的隨機、雙盲安慰劑對照、單劑量、安全性、耐受性、藥代動力學研究。第二代GKA是一種具有優化的理化性質的新分子實體，擁有新專利，為多格列艾汀（HMS5552）前藥。該項研究設計為每日一次口服給藥，旨在通過緩釋技術來延長藥物在體內的作用時間、改善患者依從性以及延長刺激腸道內GLP-1分泌的效果。這一單次劑量遞增（SAD）研究結果顯示，HM-002-1005片在人體內可迅速轉化為HMS5552，前藥在血漿和尿液中的暴露量極低。HM-002-1005片單次給藥後的t1/2（生物半衰期）相較於多格列艾汀片延長。184.5mg單次給藥後，血漿中HMS5552的Cmax與多格列艾汀片75mg單次給藥後的血漿HMS5552濃度相當；同時，血漿中HMS5552的單日AUC與多格列艾汀片75mg一天兩次給藥後HMS5552的暴露水平相當。該研究表明，HM-002-1005片在人體內幾乎完全轉化為HMS5552，且其藥代動力學特徵支持每日一次口服給藥方式。HM-002-1005片的開發不僅有利於提高患者服藥的依從性，實現24小時內有效控制血糖；同時，也為探索每日150mg以上的最大耐受劑量提供了機會，以獲得更好的治療效果。多格列艾汀75mg每日兩次（BID）劑量是根據最低有效治療劑量的治療理念，針對中國2型糖尿病患者普遍存在的胰島素分泌缺陷和早相胰島素分泌顯著降低而開發的劑型。西方2型糖尿病患者具有不同的疾病特點，往往合併肥胖症狀，多格列艾汀能夠促進GLP-1分泌、改善胰島素敏感性，有望為該患者群體帶來新的獲益。該研究結果確認HM-002-1005片184.5mg的暴露水平與多格列艾汀片75mg BID相當，公司將進一步優化劑型，在中國和美國進行第二代GKA的多次遞增劑量（MAD）臨床開發。華領醫藥創始人、CEO陳力博士表示：「華領醫藥始終致力於通過修復患者血糖自主調控能力，從源頭上治療2型糖尿病。公司歷經十年，選擇了針對大多數中國糖尿病患者安全有效的用藥劑量方案和臨床研究方案，實現了GKA的成功開發和多格列艾汀的臨床應用。在此基礎上，公司將進行戰略升級，通過繼續探索GKA的用藥潛力、豐富產品管線，在國內外尋求合作夥伴，惠及更多患者人群、拓展全球市場，更好地實現GKA藥物的品牌建設和全球首創新藥的商業價值。」關於華領華領醫藥（「本公司」）是一家總部位於中國上海的創新藥物研發和商業化公司，在美國、中國香港設立了公司。華領醫藥專注於未被滿足的醫療需求，為全球患者開發全新療法。華領醫藥匯聚全球醫藥行業高素質人才，融合全球創新技術，依託全球優勢資源，研究開發突破性的技術和產品，引領全球糖尿病醫療創新。公司核心產品華堂寧(R)（多格列艾汀片）以葡萄糖傳感器葡萄糖激酶為靶點，提升2型糖尿病患者的葡萄糖敏感性，改善患者血糖穩態失調。2022年9月30日，華堂寧(R)已獲得中國國家藥品監督管理局（NMPA）的上市批准，用於單獨用藥或者與二甲雙胍聯合用藥，治療成人2型糖尿病。對於腎功能不全患者，無需調整劑量，是一款可用於腎功能損傷的2型糖尿病患者的口服降糖藥物。詳情垂詢華領醫藥網址：www.huamedicine.com投資者電郵：ir@huamedicine.com媒體電郵：pr@huamedicine.com Copyright 2024 亞太商訊 via SeaPRwire.com.

香港, 2024年11月30日 - (亞太商訊 via SeaPRwire.com) - 華領醫藥（「公司」，香港聯交所股份代號：2552.HK）今天在第九屆中國醫藥創新與投資大會（The China BioMed Innovation and Investment Conference，以下簡稱CBIIC）上宣佈，公司已經成功完成與香港中文大學Juliana Chan教授團隊合作開展SENSITIZE研究，該研究為多格列艾汀改善β細胞葡萄糖敏感性的作用機制研究。SENSITIZE研究是由國際內分泌專家、香港中文大學Juliana Chan教授作為研究者發起的，首個在亞洲人群中採用高葡萄糖鉗夾技術評估GKA對不同血糖調節受損人群的β細胞葡萄糖敏感性影響的臨床研究，以探索不同葡萄糖激酶（GK）功能損傷類型在血糖失調方面的臨床特徵和干預手段，為研究亞洲T2D病生理及GK在血糖調控中的核心作用提供了新的科學依據。此次報告的SENSITIZE 2研究結果顯示，採用高葡萄糖鉗夾技術，多格列艾汀單次給藥修復GK酶活性，顯著改善葡萄糖耐量異常（IGT）人群的二相胰島素分泌和β細胞葡萄糖敏感性。而此前在2022年美國ADA年會上報告的SENSITIZE 1研究結果顯示，多格列艾汀可直接修復臨床納入的GK突變型活性，可以顯著改善葡萄糖激酶單基因遺傳突變糖尿病 (GCK-MODY或MODY-2)患者的胰島素第二時相分泌和β細胞葡萄糖敏感性，可以顯著改善初發2型糖尿病患者的基礎胰島素分泌。華領醫藥還將繼續研究多格列艾汀多次給藥對中間高血糖（IH）和2型糖尿病患者β細胞葡萄糖敏感性的修復作用，以及對腸促胰島素的作用，從而建立糖尿病前期和2型糖尿病患者的個性化干預和治療管理方案。關於華領華領醫藥（「本公司」）是一家總部位於中國上海的創新藥物研發和商業化公司，在美國、中國香港設立了公司。華領醫藥專注於未被滿足的醫療需求，為全球患者開發全新療法。華領醫藥匯聚全球醫藥行業高素質人才，融合全球創新技術，依託全球優勢資源，研究開發突破性的技術和產品，引領全球糖尿病醫療創新。公司核心產品華堂寧(R)（多格列艾汀片）以葡萄糖傳感器葡萄糖激酶為靶點，提升2型糖尿病患者的葡萄糖敏感性，改善患者血糖穩態失調。2022年9月30日，華堂寧(R)已獲得中國國家藥品監督管理局（NMPA）的上市批准，用於單獨用藥或者與二甲雙胍聯合用藥，治療成人2型糖尿病。對於腎功能不全患者，無需調整劑量，是一款可用於腎功能損傷的2型糖尿病患者的口服降糖藥物。詳情垂詢華領醫藥網址：www.huamedicine.com投資者電郵：ir@huamedicine.com媒體電郵：pr@huamedicine.com Copyright 2024 亞太商訊 via SeaPRwire.com.

- 天然氣總銷量達171.3億立方米；- 累計接駁居民、工業和商業用戶分別達到4,795.6萬戶、2.6萬戶及38.5萬戶；- 天然氣順價加快落地 銷氣毛差同比上漲0.02元/m³至0.59元/m³；- 增值服務經營性利潤同比增長15.4%至10.0億港元；- 財務狀況穩健，財務資源豐富，自由現金流達22.2億港元，備用銀行授信及獲批准的人民幣債券總額約1,049.1億等值港元；- 中期派息每股15.0港仙。財務摘要 截至9月30日止六個月 20242023變化千港元千港元%收入35,105,20236,049,154(2.6)    天然氣銷售19,641,83621,718,489(9.6)    燃氣接駁2,027,0382,308,096(12.2)    工程設計、建設及施工  1,308,4871,056,41223.9    液化石油氣（「LPG」）銷售9,557,9768,421,66313.5    增值服務                 2,012,9951,804,48611.6    其他業務556,870740,008(24.7)毛利5,855,6955,723,5732.3期間溢利2,263,9152,107,2037.4每股盈利（港仙）32.734.0(3.8)每股中期股息（港仙）15.015.0-  20249月30日20243月31日 變化千港元千港元%總資產153,473,528148,697,7243.2權益總額64,165,44260,747,3535.6銀行結餘及現金9,421,5978,280,33513.8香港, 2024年11月30日 - (亞太商訊 via SeaPRwire.com) - 國內具有領先地位的城市燃氣營運商中國燃氣控股有限公司（「中國燃氣」或「集團」；股票編號：384）宣布其截至2024年9月30日止（「報告期」）之上半財年業績。報告期內，為適時應對複雜多變的國際政治和經濟形勢，中國政府於九月開始推出穩定經濟的措施。在一攬子有利政策的推動下，內地宏觀經濟有望持續回升向好，同時亦為提振天然氣消費需求創造有利條件，城市燃氣企業的盈利能力有望迎來修復，進入一個嶄新發展期。此外，天然氣上下游價格聯動機制在全國範圍內逐步落地，更多地區實現居民終端銷售價格調整，銷氣毛差逐漸修復，進一步支撐天然氣行業的健康及可持續發展。集團秉承「促回款、擴毛差、降費用、強組織、提品質、謀發展」的經營理念，積極探索創新業務的增長新路徑，實現以燃氣業務、增值服務、綜合能源三大核心業務板塊的協同發展。期內，集團錄得營業額351.1億港元，天然氣售氣總量達171.3億立方米，自由現金流表現穩健，達22.2億港元。董事會通過派付上半財年股息每股15.0港仙（2023/24年上半財年：15.0港仙），以回饋廣大股東對集團的長期支持。加快天然氣順價落地，順價比例及毛差進一步提高期內，集團抓住政策機遇，積極響應國家出台的天然氣上下遊價格聯動機制及配氣價格成本監審等政策，推動各地加快順價，集團經營區域內新增20個市/縣落實調價。截至2024年9月30日，集團累計完成居民氣量順價比例達62.2%，毛差修復至0.59元/m³，與去年相比取得穩步提升。期內，借助「老舊小區改造」和「瓶改管」等政策紅利，新接駁904,232戶居民用戶、1,316戶工業用戶及24,906戶商業用戶。截至2024年9月30日，集團累計共為47,955,499戶居民用戶、25,792戶工業用戶及384,504戶商業用戶提供天然氣服務，分別較去年同期增長約3.2%、10.7%和11.6%；集團城市燃氣項目覆蓋的可接駁戶數達5,460萬戶。截至2024年9月30日，集團累計共於30個省、市、自治區取得662個擁有專營權的管道燃氣項目，並擁有32個天然氣長輸管道、509座壓縮/液化天然氣加氣站、一個煤層氣開發項目及120個液化石油氣分銷項目。LPG業務保持高質量發展，持續優化縱向一體化協同作為中國規模最大、產業鏈最完整的綜合性LPG運營服務商，集團業務覆蓋全國22個省、市、自治區，目前運營5座液化石油氣專用碼頭及6座大型石化產品倉儲物流基地，碼頭年吞吐能力超過1,000萬噸，總庫容超過80萬立方米。期內，集團實現銷售液化石油氣201.8萬噸，銷售收入總額達到95.6億港元。集團持續優化縱向一體化協同，就上游而言，集團積極推進核心能力建設，提升國際貿易業務能力。期內，集團重構國際貿易團隊和貿易風控體系，設立新加坡國際直採平台，在國際貿易業務方面取得實質性突破。於中游，集團推進倉儲物流市場化運作，實現倉儲物流資源整合，逐步提升倉儲周轉率，同時啟動國內運貿平台建設，利用數字化賦能，擴大國內分銷能力，從而提高國內分銷與倉儲物流效益。在下游端，集團推動創新業務模式與輕資產模式有效結合，通過迭代優化終端投資模式，豐富投資工具，助力終端業務高質量發展。增值服務營收利潤雙增長，未來發展空間巨大基於家庭場景，集團增值服務佈局3大傳統產品板塊（廚房產品、安防產品、其它產品及服務）及4大新產品板塊（電器、宜居、到家、優選）。目前增值服務業務遍及全國26個省、市、自治區，為用戶提供產品及服務，不斷增加用戶覆蓋，拓寬銷售渠道。今年以來，中國消費市場保持穩定增長態勢，政府出台多項政策鼓勵家電以舊換新和家裝消費品換新工程。集團把握政策機遇，於期內通過加快渠道建設、優化運營策略和強化終端賦能，實現增值服務收入同比增長11.6%至20.1億港元；經營性利潤同比增長15.4%至10.0億港元。目前，集團通過不斷深化傳統渠道運營策略，優化產品結構，加快新業務拓展步伐，借助國家消費扶持政策，進一步擴大市場規模，未來發展空間巨大。積極探索綜合能源業務商業模式，推進重點業務發展集團堅持以「綠色城市運營商」為戰略定位，有效推進多業態融合、優化低能源成本綜合方案以拓展市場、落地可長期發展的多贏商業模式。集團充分利用自身燃氣項目的巨大市場和用戶優勢，通過外延式及內生性增長提升綜合能源業務市場份額。期內，集團積極探索綜合能源業務發展模式，錨定發展重點，投資及運營工商業用戶側儲能、分佈式光伏、鍋爐節能、工商用戶節能、建築能效、充電樁、生物質能等業務。同時積極參與售電業務，並帶動綠電綠證、碳排放因子庫、虛擬電廠等業態快速擴充，為客戶提供高效率的綜合能源，滿足客戶對氣、熱、電、冷的不同需求。期內，儲能及綜合能效業務累計實現簽約總裝機容量318.4MWh，累計投建255.8MWh；售電業務交易量28.1億度；綠證綠電業務完成銷售8,196.4MWh。持續提升安全管理能力，積極推進老舊燃氣管道等設施整改工作集團始終將安全管理視為核心任務，全面識別潜在風險，認真落實隱患整改，持續提升安全管理能力，為集團高質量發展營造安全穩定的環境。期內，集團通過開展專項治理工作，進一步規範基層員工操作，提升員工業務水平，並加强對燃氣管道和相關設施關鍵信息的系統性收集，提升對管網資産的管理水平。同時，借助國家政策支持，集團積極推進老舊燃氣管道和用戶設施老化的更新改造與維護工作。此外，集團不斷加强HSE體系審核認證及體系建設工作，建立健全集團雙重預防機制管理模式，加强安全風險管控與隱患排查治理的閉環管理，並通過積極開展評級檢查，有效提升了項目公司的安全管理水平。財務狀况穩健截至2024年9月30日，集團總資產為1,534.7億港元；銀行結餘及現金為94.2億港元；期內集團通過執行嚴格的外幣債務管理措施，及時合理地調整債務結構。集團一直積極與中國（包括香港）及外資銀行建立長遠合作關係，備用銀行授信及獲批准的人民幣債券總額約1,049.1億等值港元。行業發展及展望國際天然氣價格在經歷兩年劇烈波動後，二零二四年以來重現平衡，供需端亦延續寬鬆態勢。9月下旬開始，中國政府推出一系列穩經濟、強信心的刺激政策，有助於經濟復甦和房地產市場穩定，加上此前推出的「三大工程」、「超長期特別國債」、「老舊管網更新」、「老舊小區改造」、「瓶改管」等利好燃氣行業的政策，有利於穩固燃氣行業根基。與此同時，各省市陸續發布和落實天然氣上下游價格聯動政策，有助於提升銷氣毛差，保障燃氣企業的合理收益，促進天然氣行業的健康長遠發展。此外，全球低碳轉型的浪潮不可阻擋，新能源和綜合能源持續發展。集團將緊抓政策機遇，加快促進順價落地，嚴控資本開支，推動數字化轉型，進一步提升銷氣量及增值服務盈利水平，並全力推動綜合能源項目發展，為國家經濟發展提供「綠色」保障。集團主席兼總裁劉明輝先生表示：「隨著今年九月中國政府推出一系列旨在穩定市場的貨幣及財政政策以促進經濟長期健康發展，相信更多具體、有力的穩經濟政策將陸續出台，這些措施將提振資本市場信心，同時亦為中燃的業務發展提供良好的宏觀環境。在宏觀經濟逐漸向好的大環境下，集團將發揮勇於創新變革的優良傳統，不斷優化業務模式，堅持高質量發展和可持續發展的策略，在不斷做強集團燃氣業務的基礎上，繼續深耕『客戶導向』和『價值創造』，依託產業鏈延伸，拓展用戶側儲能、生物質能等新業務，積極探索宜居、到家等增值服務新業態。同時，集團亦將把握機遇，緊跟政策、用好政策，縝密籌劃，真正把國家政策紅利轉化為集團發展新動能，實現經營業績與股東利益的雙重增長。」有關中國燃氣中國燃氣控股有限公司（「中國燃氣」，股票代號：384）是一家領先的燃氣運營服務商，主要於中國從事投資、建設、經營城市燃氣管道基礎設施，向居民及工商業用戶輸送天然氣和液化石油氣，建設和經營車船用天然氣加氣站。同時，在龐大的燃氣用戶網絡基礎上，中國燃氣打造了增值服務及綜合能源並舉的全業態發展結構。目前中國燃氣在全國已擁有662個城鎮的管道燃氣專營權項目、32個天然氣長輸管道項目、509座壓縮/液化天然氣加氣站，以及液化天然氣等能源產品的進出口經營權，並擁有120個液化石油氣分銷項目。如欲獲得更多中國燃氣的資訊，請登入公司網址http://www.chinagasholdings.com.hk Copyright 2024 亞太商訊 via SeaPRwire.com.